Literature DB >> 25778783

Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea.

Sang Soo Lee1, Sook-Hyang Jeong2, Eun Sun Jang2, Young Seok Kim3, Youn Jae Lee4, Eun Uk Jung4, In Hee Kim5, Si Hyun Bae6, Han Chu Lee7, Mee-Kyung Kee8, Chun Kang8.   

Abstract

BACKGROUND AND AIMS: The outcomes of hepatitis C virus (HCV)-related liver cirrhosis was limitedly studied in a hepatitis B virus-endemic area. This multicenter, prospective cohort study was conducted to elucidate the incidence of hepatocellular carcinoma (HCC) and mortality in the Korean patients with HCV-related cirrhosis.
METHODS: From January 2007 through June 2012, 196 patients with HCV-related cirrhosis were prospectively enrolled and regularly followed at six university hospitals to determine HCC occurrence and mortality. A multivariable analysis using Cox proportional hazards regression was performed to clarify the related factors to the outcomes.
RESULTS: During a mean follow-up period of 39.2 months, 31 (15.8%) patients developed HCC, and 33 (16.8%) patients died or underwent liver transplantation. The estimated HCC incidence was 5.8 per 100 person-years, and the independent factors for HCC were absence of anti-HBV surface antibody (HBs hazard ratio [HR], 5.018; 95% confidence interval [CI], 1.710-14.726; P = 0.003) and serum albumin < 3.8 g/dL (HR, 3.051; 95% CI, 1.318-7.067; P = 0.009). The overall mortality rate was 5.1 per 100 person-years, and the related independent factors were the presence of ascites (HR, 2.448; 95% CI, 1.142-5.210; P = 0.022), serum albumin < 3.8 g/dL (HR, 3.067; 95% CI, 1.254-8.139, P = 0.014), and nonachievement of sustained virologic response (SVR) (HR, 0.066; 95% CI, 0.001-0.484, P = 0.002).
CONCLUSION: The incidence of HCC in HCV-related cirrhosis seems to be high in Korea, and advanced liver disease and no achievement of SVR were associated with mortality. The absence of anti-HBs in hepatocarcinogenesis related to HCV warrants further study.
© 2015 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  hepatitis B virus; hepatitis C virus; hepatocellular carcinoma; liver cirrhosis; mortality

Mesh:

Substances:

Year:  2015        PMID: 25778783     DOI: 10.1111/jgh.12950

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  9 in total

Review 1.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

2.  Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures.

Authors:  Andrea Messori; Brigitta Badiani; Sabrina Trippoli
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

3.  Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.

Authors:  Nicola Coppola; Lorenzo Onorato; Caterina Sagnelli; Evangelista Sagnelli; Italo F Angelillo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 4.  Current status of hepatitis C virus infection and countermeasures in South Korea.

Authors:  Sook-Hyang Jeong; Eun Sun Jang; Hwa Young Choi; Kyung-Ah Kim; Wankyo Chung; Moran Ki
Journal:  Epidemiol Health       Date:  2017-04-13

5.  Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs.

Authors:  Seung Ho Lee; Young-Joo Jin; Jun Young Shin; Jin-Woo Lee
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

6.  Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma.

Authors:  Hye Kyong Park; Sang Soo Lee; Chang Bin Im; Changjo Im; Ra Ri Cha; Wan Soo Kim; Hyun Chin Cho; Jae Min Lee; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok-Jae Lee
Journal:  BMC Cancer       Date:  2019-08-20       Impact factor: 4.430

7.  A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.

Authors:  Hye-Lin Kim; Kyung-Ah Kim; Gwang Hyun Choi; Eun Sun Jang; Moran Ki; Hwa Young Choi; Sook-Hyang Jeong
Journal:  Clin Mol Hepatol       Date:  2021-11-05

8.  The Serious Challenge of Occult Hepatitis B Virus Infection-Related Hepatocellular Carcinoma in China.

Authors:  Renxiang Xia; Jing Peng; Jian He; Ping Jiang; Chunyan Yuan; Xiaoli Liu; Yunqing Yao
Journal:  Front Microbiol       Date:  2022-02-07       Impact factor: 5.640

9.  Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.

Authors:  Ra Ri Cha; Sang Soo Lee; Chang Min Lee; Sung Bok Ji; Hee Cheul Jung; Hyun Chin Cho; Jin Joo Kim; Jae Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae-Hyo Kim; Woon Tae Jung; Ok-Jae Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.